Core Insights - Avacta Therapeutics will present updated data from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 ESMO Congress in Berlin from October 17-21, 2025 [1][2] - FAP-Dox is a peptide drug conjugate designed to target FAP-positive solid tumors, utilizing a mechanism that cleaves doxorubicin specifically in the tumor microenvironment [1][5] Company Overview - Avacta Therapeutics is a clinical-stage life sciences company focused on developing targeted oncology drugs through its proprietary pre|CISION platform [5][6] - The pre|CISION platform aims to deliver highly potent cancer therapies by concentrating drug payloads in the tumor microenvironment while minimizing exposure to normal tissues [5][6] Clinical Trial Details - The Phase 1a trial of FAP-Dox has completed the enrollment dose escalation phase, with ongoing patient enrollment in multiple dose expansion cohorts for a Phase 1b study [2] - The presentation at ESMO will include data from patients with FAP-positive solid tumors, highlighting the drug's targeted approach [2][3]